Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2638

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2638
---
 outbreak of disease or other natural disasters and civil unrest.

Our
operations may be adversely affected by fire, climate events, or other manmade or natural disasters or incidents, and our business continuity
and disaster recovery plans may not adequately protect us from a serious disaster or event. Such incidents or events may result in us
being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, or of our collaborators,
and thus may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and may have significant
negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays
in the development of our product candidates or interruption of our business operations. Natural or manmade disasters could further disrupt
our operations, and have a material and adverse effect on our business, financial condition, results of operations and prospects. If
a natural disaster, power outage, fire or other event occurred that prevented us from using all or a significant portion of our critical
infrastructure, such as our research facilities or the research or manufacturing facilities of our third-party collaborators, or that
otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial
period of time.

Our
disaster recovery and business continuity plans may prove inadequate in the event of a serious disaster or similar event. We may incur
substantial expenses as a result of the limited nature of our disaster recovery, insurance coverage, and business continuity plans, which
could have a material adverse effect on our business.

106

Risks
Related to Growing Our Organization

We
may encounter difficulties in managing our growth, which could adversely affect our operations.

As
our clinical development and commercialization plans and strategies develop, and as we transition into operating as a public company,
we will need to expand our managerial, clinical, regulatory, sales, marketing, financial, development, manufacturing and legal capabilities
or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage
additional relationships with various strategic collaborators, suppliers and other third parties. Our future growth would impose significant
added responsibilities on members of management, including:

    ●
    identifying,
    recruiting, integrating, maintaining and motivating additional employees;

    ●
    managing
    our development and commercialization efforts effectively, including the clinical and FDA review process for our product candidates,
    while complying with our contractual obligations to